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ABSTRACT 
 
The coherent body of research described in the existing published work is 
concerned with new assay method development and validation using novel 
systematic approaches for pharmaceutical and diagnostic compounds. 
 
The first stage of the research was to study how analytical method development 
and validation are typically carried out at present and to formulate this into a 
simple step-by-step approach. Such a template and protocol was not only used 
as the foundation of this research programme but could also serve as a simple 
systematic guide for other practitioners and those new to the field. Furthermore, 
it was recognised that this protocol should satisfy the requirements of the most 
strategically important regulatory agencies. 
 
The second stage of this research involved evaluation and application of the 
above validation approach to new methods that were developed for a diverse 
range of analytes and samples. A new purity assay for 1,10-phenanthroline-5,6-
dione and 4,7-phenanthroline-5,6-dione using high-performance liquid 
chromatography (HPLC) was developed and validated. Impurities in these 
compounds were identified by liquid chromatography-mass spectrometry (LC-
MS). Best practice in method development and validation is equally important in 
the analysis of both active components and excipients in formulated products. In 
the first case, a liquid chromatography assay method for determining the content 
of 2-(diethylamino)-N-(2,6-dimethylphenyl) acetamide in a gel formulation was 
developed and validated. In the second case, the individual contents of three p-
hydroxy benzoic acid ester preservatives in a complex multi-component sample 
were determined following the development and validation of a liquid 
chromatography method.  
 
Finally, the validation approach was evaluated as applied to another analytical 
technique. Here, gas chromatography (GC) successfully used to develop a novel 
assay for p -cymene in tea tree oil formulations presented different analytical 
problems because of the very complex nature of this natural product. Stability 
study information to increase the shelf life of the product and validation data for 
the analytical method for p-cymene content was critically evaluated.  
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In essence, the critical review of the requirements for method validation for 
various agencies and the subsequent preparation of guidelines on how to go 
about method validation have had a significant impact on how analytical 
practitioners worldwide go about method development and, more importantly, 
method validation. Further it was possible to apply these guidelines to conduct a 
series of effective, successful method validation for assays involving a range of 
typical pharmaceutical samples. 
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1 Introduction 
 
 
Analytical method development and validation is an important part of analytical 
chemistry and plays a major role in the discovery, development, and 
manufacture of pharmaceuticals. The official test methods that result from these 
processes are used by quality control laboratories to ensure the identity, purity, 
potency and performance of drug product ‘quality’ essential for drug safety and 
efficacy. 
 
In the diagnostics and biotechnology industries and even more so in the 
pharmaceutical industry, a current major issue is the high cost of research in 
introduction of new drugs. In essence it takes several hundred million dollars to 
discover, develop and gain regulatory approval. One of the reasons research 
and development (R&D) is so costly in pharmaceuticals is that most new drug 
candidates fail to reach the market. Failure can result from toxicity, 
carcinogenicity, manufacturing difficulties, inadequate efficacy and analytical 
problems. Therefore there is a need for high throughput in order to maximise 
patent lifetime and consequently generate the profits to support the research and 
to increase the speed with which products can be delivered to the market. All the 
different stages of pharmaceutical R&D is underpinned by analysis so that high 
throughput is acutely dependent on effective and efficient analysis within which 
simple effective method development and comprehensive analytical method 
validation is of fundamental importance (Shabir et al., 2007a). 
 
A wide variety of materials are used in the pharmaceutical and diagnostic 
industries. All of these materials must be analysed in some way or other and, just 
as importantly, the method of analysis must be validated i.e. it must be shown 
that the method is fit for its intended purpose. 
 
In the pharmaceutical field, method validation is very much a major issue as 
analysis is used primarily to control drug quality. This is important in its own right 
and also in that drug safety and efficacy are dependent on it. Different chemical 
entities with varying chemical and physical properties are used. These may 
include starting materials, intermediates, final drug substances and the final  
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formulated pharmaceutical products. The pharmaceutical analyst will be 
concerned with applying analytical methods to the determination of stability/shelf 
life, purity, side-product identity, dissolution etc. Here, the analyst is required to 
develop new methods of analysis appropriate to the information required. In 
many cases, the analyte may be known but is present in a new sample matrix 
such that a new sample preparation method is needed. The knowledge gained in 
the method R&D phase is important when it comes to validating the research 
data efficiently. This is an important coherent theme that runs throughout the 
publications on which this thesis is based. 
 
Frequently, high-performance liquid chromatography (HPLC) is the analytical 
method of choice in pharmaceutical analysis [3, appendix I] because of its 
specificity (i.e. all the components of a sample are separated from one another 
before the measurement is made so that its results arise from the analyte and 
from nothing else). Although HPLC is a relatively mature technique, the analyst 
is continually required to innovate by adapting current methodology or indeed 
developing completely new protocols. For example, the coupling of HPLC with 
another technique such as mass spectrometry (MS) can be an especially 
powerful tool [5, appendix I]. 
 
In the diagnostic field, the variety of materials is further expanded due to the 
complexity of medical devices and their corresponding reagents. Such materials 
may include polymers, surfactants, enzymes, cofactors, mediators, stabilisers 
etc. The diagnostic analyst is therefore required to apply other techniques apart 
from HPLC in the analysis of key materials. An in-depth knowledge of the 
materials and their critical properties as applied to their use in the diagnostic 
device is necessary. Innovation is again needed if there is no directly applicable 
methodology reported in the literature. Once an analytical method is developed, 
validation is conducted in order to prove its results of the research are valid and 
its use for the intended application.  
 
Method validation is a critical step for any product release for marketing 
authorisation. The literature contains diverse approaches to performing method 
validation (Crowther, 2001; Wilson, 1990; Clarke, 1994; Bressolle et al., 1996;  
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Carr & Wahlich 1990; Green, 1996; Trullols et al., 2004; Ermer, 2001; 
Daraghmeh, 2001; Badea et al., 2004; Mendez et al., 2003).  
 
Many analytical methods appearing in the literature have not been through a 
thorough validation exercise and thus should be treated with caution until full 
validation has been carried out. Also there is no method validation reported with 
GMP/GLP considerations. Validation of a new method is a costly and very time-
consuming exercise. However the result of not carrying out method validation 
could result in litigation, failure to get product approval, costly repeat analysis 
and loss of business and market share (Harvey et al., 2002).   
 
Currently, there is no completely worldwide single source or final guideline on 
method validation [4, appendix I] that helps analysts to perform validation in a 
systematic manner and most importantly under GMP/GLP considerations. 
Therefore industry depends on the analyst’s knowledge and experience to 
develop simple and efficient methods of analysis.  
 
The other major problem pharmaceutical industries are facing in today’s world is 
that different validation data requirements are required for regulatory 
submissions for medicinal products’ registration/approval depending upon the 
location of the regulatory body. For example the release of any medicinal product 
in USA, Europe and Japan would require the use of International Conference on 
Harmonisation (ICH) method validation criteria. (ICH, 2005). However, the 
release of the very same product, by the same industry, in any other part of the 
world would force the use of their local regulatory guidelines.  This inevitably 
becomes a costly process due to issues of documentation and personnel training 
etc. Therefore, efforts are underway to streamline the method validation process 
through an idea commonly referred to as Harmonisation by ICH.  
 
The birth of ICH took place at a meeting in April 1990, hosted by the European 
Federation of Pharmaceutical Industries and Associations (EFPIA) in Brussels. 
Representatives of the regulatory agencies and industry associations of Europe, 
Japan and the USA met, primarily, to plan an international conference but the 
meeting also discussed the wider implications and terms of reference of ICH.  
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The ICH Steering Committee, which was established at that meeting, has since 
met at least twice a year, with the location rotating between the three regions. 
 
ICH is a joint initiative involving both regulators and industry as equal partners in 
the scientific and technical discussions of the testing procedures which are 
required to ensure and assess the safety, quality and efficacy of medicines. The 
focus of ICH has been on the technical requirements for medicinal products 
containing new drugs. The vast majority of those new drugs and medicines are 
developed in Western Europe, Japan and the United States of America and 
therefore, when ICH was established, it was agreed that its scope would be 
confined to registration in those three regions. 
 
ICH is comprised of six parties that are directly involved, as well as three 
observers and the International Federation of Pharmaceutical Manufacturers & 
Associations (IFPMA). The six parties are the founder members of ICH that 
represent the regulatory bodies and the research-based industry in the European 
Union, Japan and the USA. These parties include the European Union (EU), 
European Federation of Pharmaceutical Industries and Associations (EFPIA), 
The Ministry of Health, Labour and Welfare, Japan (MHLW), Japan 
Pharmaceutical Manufacturers Association (JPMA), US Food and Drug 
Administration (FDA) and Pharmaceutical Research and Manufacturers of 
America  (PhRMA). 
 
The European Commission represents the 27 members of the EU. The 
Commission works through harmonisation of legislation and technical 
requirements and procedures, to achieve a single market in pharmaceuticals to 
allow free movement of products throughout the EU. The European Medicines 
Agency (EMEA) has been established by the Commission and is situated in 
London.  
 
EFPIA is situated in Brussels and has, as its members, 29 national 
pharmaceutical industry associations and 45 leading pharmaceutical companies 
involved in the research, development and manufacturing of medicinal products 
in Europe for human use. Much of the Federation's work is concerned with the 
activities of the European Commission and the EMEA.  
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MHLW has responsibilities for approval and administration of drugs, medical 
devices and cosmetics in Japan. Technical and scientific support for ICH 
activities are provided by the Pharmaceuticals and Medical Devices Agency 
(PMDA) (which was established in April 2004 as a new administrative agency for 
scientific review for drug approval), and by the National Institute of Health 
Sciences (NIHS) and other experts from academia. 
 
JPMA represents 75 members (including 20 foreign affiliates) and 14 
committees. Membership includes all the major research-based pharmaceutical 
manufacturers in Japan. ICH work is coordinated through specialised 
committees of industry experts who also participate in the Expert Working 
Groups. 
 
The FDA has a wide range of responsibilities for drugs, biological, medical 
devices, cosmetics and radiological products. The largest of the world's drug 
regulatory agencies FDA is responsible for the approval of all drug products used 
in the USA. The FDA consists of administrative, scientific and regulatory staffs 
organised under the Office of the Commissioner and have several Centres with 
responsibility for the various products that are regulated. Technical advice and 
experts for ICH work are drawn from the Centre for Drug Evaluation and 
Research (CDER) and the Centre for Biologics Evaluation and Research 
(CBER). 
 
PhRMA represents the research-based industry in the USA. The Association has 
67 companies in membership, which are involved in the discovery, development 
and manufacture of prescription medicines. PhRMA, which was previously 
known as the US Pharmaceutical Manufacturers Association (PMA), coordinates 
its technical input to ICH through its Scientific and Regulatory Section. Special 
committees have been set up, of experts from PhRMA companies, to deal with 
ICH topics.  
  
Since ICH was initiated, in 1990, there have been observers to act as a link with 
non-ICH countries and regions. The ICH observers are: the World Health 
Organisation (WHO); the European Free Trade Association (EFTA), currently 
represented at ICH by Swissmedic Switzerland and Health Canada.  
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IFPMA is a non-profit, non-governmental organization representing national 
industry associations and companies from both developed and developing 
countries. Member companies of the IFPMA are research-based pharmaceutical, 
biotech and vaccine companies. IFPMA has been closely associated with ICH, 
since its inception to ensure contact with the research-based industry, outside 
the ICH Regions. IFPMA provides the ICH Secretariat.  
  
ICH is administered by the ICH Steering Committee that is supported by the ICH 
Secretariat. The ICH Steering Committee was established in April 1990, when 
ICH was initiated. The Steering Committee, working with the ICH Terms of 
Reference, determines the policies and procedures for ICH, selects topics for 
harmonisation and monitors the progress of harmonisation initiatives. The 
Steering Committee meets at least twice a year with the location rotating 
between the three regions. The Secretariat operates from the IFPMA offices, in 
Geneva, and is primarily concerned with preparations for, and documentation of, 
meetings of the Steering Committee as well as coordination of preparations for 
Working Group and Discussion Group meetings.  
 
The first guideline on method validation (Q2: Text on Validation of Analytical 
Procedures) was approved by the Steering Committee under ICH Step 2 and 
release for public consultation in October 1993. This guideline was then finalised 
as Q2A and approved under ICH Step 4 and recommended for adoption to the 
three ICH regulatory bodies in October 1994. The second guideline on method 
validation Q2B (Validation of Analytical Procedures: Methodology) was 
developed to complement the Parent Guideline and approved by the Steering 
Committee under Step 2 and release for public consultation in November 1995. 
Q2B was approval by the Steering Committee under Step 4 and recommended 
for adoption to the three ICH regulatory bodies in November 1996. In November 
2005, the parent guidelines Q2A and Q2B were renamed Q2(R1). The new title 
is “Validation of Analytical Procedures: Text and Methodology”.  
 
Method validation is the proof needed to ensure that an analytical method can 
produce results that are valid, reliable, reproducible and are fit for the purpose 
intended.  Choosing the validation criteria depends on the method type [see 
paper 4]. In general, method validation parameters that should be studied are  
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linearity, range, accuracy, precision (repeatability and intermediate precision), 
specificity, limit of detection and limit of quantitation. The detailed explanation of 
these parameters is published in ICH Q2(R1) and in papers 2 and 4 (appendix I) 
including a step-by-step approach. Here only brief definitions are given. 
Accuracy: Closeness of agreement between the value obtained by the method 
and the true value. Precision: Expresses the closeness of agreement between a 
series of measurements obtained from multiple sampling. Precision is often 
expressed as the relative standard deviation of replicate measurements. 
Specificity: The ability to measure the analyte in the presence of components, 
which we expect to be present in the sample matrix.  Limit of detection: The 
lowest amount of analyte in a sample that can be detected, but not necessarily 
quantitated. Usually the lowest limit is evaluated as the signal-to-noise (s/n) ratio 
that is equivalent to 3 times the standard deviation of the noise (s/n = 3σ). Limit 
of Quantitation: The lowest amount of analyte in a sample that can be 
quantitated with suitable precision and accuracy. Usually the quantitation limit is 
evaluated as the s/n ratio that is equivalent to 10 times the standard deviation of 
the noise (s/n = 10σ). Linearity: The range of concentrations of analyte for which 
the procedure provides a test result that is in direct correlation to the amount of 
analyte in the sample.  
 
The outcome of ICH efforts has been accepted by most regulatory agencies and 
pharmacopoeias such as U.S. Food and Drug Administration (FDA) (FDA, 1994, 
1987), and USP (USP, 2007). 
 
The USP established in 1820, contains legally recognised standards of identity, 
strength, quality, purity, packaging and labelling for drug substances, dosage 
forms and other therapeutic products including nutritional and dietary 
supplements. USP also contains monographs, which are recognised worldwide 
and may be enforceable by the US FDA and also by state agencies in the US.  
 
The ICH guidelines achieved a great deal in harmonising the definitions of the 
required validation characteristics and their basic requirements. However, they 
provide only a basis for a general discussion of the validation parameters, their 
calculation and interpretation. However, this has not removed the confusion in 
industries because ICH, as yet, has not explained various other method types  
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such as response test (to detect a specific substance in a sample as indicated by 
test signal response), concentration test (for quantitation of a specific substance 
in a sample), physical test (for determination of the physical characteristics of a 
product or material) and cleaning test (for evaluating the cleanliness of 
equipment and areas used for manufacturing). Also ICH has not explained step-
by-step approaches and most importantly GMP/GLP considerations that required 
during method validation to meet regulatory requirements. This impacts 
regulatory submissions (Shabir et al., 2007a).  
 
The strategy described in the papers on which this thesis is based, was to 
address some specific objectives i.e. (i) to critically evaluate current practices in 
method development and validation in order to identify best practices, (ii) to 
apply best practices with some improvements, in such a way as to ensure good 
quality and provide new knowledge on a wide range of pharmaceutical 
substances, products and compounds used in pharmaceuticals, diagnostics and, 
finally, (iii) to draw upon the outcomes of the programme to be able to 
recommend the way forward with respect to ensuring that the ever-evolving 
approaches to analytical method development and validation were enhanced, 
simple, systematic, efficient and effective while still being compliant with the 
requirements of regulatory agencies. 
 
1.1  Critical evaluation of current best practice in analytical method 
development and validation 
 
The first stage of the programme was to study how analytical method 
development and validation is typically carried out at present [1, 3, appendix I] 
and to formulate this into a simple step-by-step approach. Such a systematic 
protocol template [2, appendix I] was not only used as the foundation of this 
research programme but could also serve as a simple systematic guide for other 
practitioners and those new to the field. Furthermore, it was recognised that this 
protocol should satisfy the requirements of the most strategically important 
regulatory agencies. These requirements were critically evaluated, identifying the 
key similarities and, more importantly, differences between the validation 
requirements of the FDA, USP and ICH [4, appendix I]. The aim of the field was  
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to take forward to apply the identified best practices and to studies of a diverse 
range of analytes and complicated samples.  
 
Everyday many analysts face the need and challenge to develop and validate 
HPLC, LC-MS and GC methods. Whereas individuals’ approaches may exhibit 
considerable diversity, a best practice method development and validation 
follows the systematic approach (Figure 1.1) (Shabir et al., 2007a). This is a 
highly successful approach to a method development and validation process. 
Before embarking on the development of a new method, the literature should 
always be searched to see if a suitable method already exists. If a suitable one is 
found, it will still be necessary to perform some method optimisation and 
validation to prove that the method can be successfully adapted for its intended 
use.  
Feasibility study phase
Research phase
Development phase
Optimisation phase
Characterisation phase
Validation phase
Method transfer
final phase
Plan/preparation
for project
Determine whether the assigned task can be
accomplished using available resources
Discover new knowledge on the compound in hopes that
such information will be useful in developing a new
method
Translate research findings into a new analytical method
Further improve developed method by performing
robustness study to gain greater confidence on the
generation of analytical data
Determine reliable method performance limits from the
analytical performance characteristics and set acceptance
criteria for the test method validation through protocol
Write protocol and execute using validated equipment.
Write final summary report
Ensure information/data
gained during each
phase is documented
and available
 
 
Figure 1.1 - Systematic approach in analytical method development and validation (Shabir et 
al., 2007a). 
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In the feasibility study, the analyst will determine whether the assigned task can 
be successfully accomplished by using available resources. Research is defined 
as the activity aimed at discovering new knowledge on the compound in hopes 
that such information will be useful in developing a new method.  Development is 
the translation of research findings into a new analytical method and the 
systematic use of knowledge or understanding gained from research directed 
toward the analytical methods, including the design and development of 
prototypes and processes. Robustness studies must be considered in this 
phase. Robustness: Measure of a method’s capacity to remain unaffected by 
small but deliberate variations in method parameters [4, appendix I]. 
 
The development phase must also include system suitability testing and stability 
of analytical solutions that of the mobile phase. In the optimisation phase, the 
developed method can be further improved to gain greater confidence on the 
generation of analytical data. The search for the best solution amongst 
alternatives is the extreme value of variables. The current developed approach 
emphasises the allocation of greater resources during the development and 
optimisation phases. This allows the analyst to have more confidence on the 
quality of data generated and therefore considerably reduces the resources that 
are required for the process of validation (Shabir et al., 2007a). 
 
The purpose of the characterisation study is to determine reliable method 
performance limits from the analytical performance characteristics and set 
acceptance criteria for the test method validation. As a best practice, the 
characterisation protocol needs to be written and approved before execution. 
Prior to execution of the protocol, it is necessary that the analytical system itself 
is adequately designed, maintained, calibrated and validated. In all cases proper 
validation documentation should be archived to support the qualification process. 
All personnel involved in the characterisation protocol activities must be trained 
prior to performing their function. On completion of the characterisation study, 
the results/data should be critically assessed from a statistical point of view. 
 
Validation is the last and critical step for the success of the whole method 
development project. If the validation fails, it can be seen as a wasted resource 
and inevitably can delay the product release date. Here, the validation protocol  
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needs to be written and approved by an appropriate cross-functional team. Upon 
successful completion of the validation, the data should be statistically analysed 
against its acceptance criteria by appropriate experts in order to test its validity. 
Timely implementation / method transfer plays an important role in expediting 
drug candidates through development stages. Method transfer is not a trivial task 
and requires careful planning and constant communication between the 
laboratory personnel involved in the transfer. Method transfer could occur within 
the same organisation or between pharmaceutical companies and analytical 
service providers. To have a successful transfer, the analytical method itself 
must be robust and the equipment differences between the delivering and 
receiving parties should be carefully evaluated. Unfortunately very limited 
information on method transfer can be found in the literature. Typically in any 
organisation, before the method transfer, scientists from both laboratories (R&D: 
method developer and quality control: end user) need to go through the method 
details very carefully. As a best practice in order to achieve successful transfer of 
the analytical method, a method transfer validation protocol should be prepared 
that is agreed by both sites. The approved method may then be validated (Shabir 
et al., 2007a). 
 
The second stage of the overall research programme involved evaluation and 
application of the above validation approach to methods that were developed for 
a diverse range of analytes and complex samples using analytical techniques 
such as HPLC, LC-MS and GC [5-9, appendix I]. The results / data generated 
from new validated assay methods were submitted to regulatory agencies for a 
pharmaceutical product licence for marketing authorisation. The results were 
critically reviewed by the regulatory agencies for its reliability, validity and 
approved for product licence. These validated new assay methods have been 
implemented in high compliance quality control laboratories for routine analysis 
of raw materials, bulks, intermediates and final products release. 
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2  Materials and Methods 
 
 
The experimental techniques and materials details are published in the author’s 
papers [5-9, appendix I]. Here only a brief general description of analytical 
techniques such as, reversed-phase HPLC, LC-MS and GC used in this 
research is given.   
 
A modern HPLC system is shown systematically in Figure 2.1. The equipment 
consists of a high-pressure solvent delivery system, a sample auto injector, a 
separation column, a detector (often an UV or a DAD) a computer to control the 
system and display results. Many systems include an oven for temperature 
control of the column and a pre-column that protects the analytical column from 
impurities. The actual separation takes place in the column, which is packed with 
chemically modified 3.5-10 µm (often silica) particles. A mobile phase is pumped 
through the column with the high-pressure pump and the analytes in the injected 
sample are separated depending on their degree of interaction with the particles. 
A proper choice of stationary and mobile phase is essential to reach a desired 
separation. 
 
 
Solvent
(Mobile Phase
Reservoir)
Pump
(Solvent Delivery
System)
Injector
HPLC
Column
Data Handling
Computer System
Waste
Detector
 
Figure 2.1 - Block diagram of a general LC system. 
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Reversed-phase chromatography is probably the most commonly used 
separation mechanism in liquid chromatography and consists of a non-polar 
stationary phase (normally octadecyl, C18 or octyl C8 chains) bonded to a solid 
support that is generally micro particulate silica gel. Silica has a small pH range 
(3-8) where mixtures can be separated without degradation of the column 
performance. The mobile phase is polar and, therefore, the sample compounds 
are partitioned between the mobile and the stationary phases. The separation is 
normally performed using aqueous mobile phase containing different 
percentages of organic modifiers (e.g. methanol, ethanol, acetonitrile, or 
tetrahydrofuran) to increase the selectivity between species. Solute retention is 
also influenced by eluent pH, which affects the dissociation level of the analyte 
and therefore, its partition between the mobile and stationary phases (Shabir et 
al., 2007a). 
Mass spectrometry has progressed extremely rapidly during the last decade: 
production, separation and detection of ions, data acquisition, data reduction, 
etc. and this has led to the development of entirely new modern instruments and 
applications (Niessen, 2003, Shabir et al., 2007a). 
 
The combination of chromatographic separations with mass spectrometric 
detection is considered an indispensable tool for problem solving in analytical 
chemistry and increasingly for routine analytical methods. Mass spectrometric 
detection brings an added level of information, complementary to the 
chromatographic process that improves the certainty of identification and the 
specificity of detection. Mass spectral information can generally be obtained from 
sample sizes typical of common analytical methods. In the last ten years, 
research efforts in the field of LC-MS have changed considerably. LC-MS has 
rapidly matured to become a very powerful and useful analytical tool that is 
widely applied in many areas of chemistry, pharmaceutical sciences and 
biochemistry. Investigation into the coupling of HPLC and MS began in the early 
1970s. In the first 20 years, most of the attention had to be given to solving 
interface problems and building new technology. However, most scientists with 
LC-MS today are only concerned with application of the commercially available 
techniques in their field of interest. Technological problems in interfacing appear 
to be solved, and from the wide variety of interfaces developed over the years 
basically only two dominate, i.e. electrospray ionisation (ESI) and atmospheric- 
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pressure chemical ionisation (APCI), which are both atmospheric-pressure 
ionisation (API) techniques (Shabir et al., 2007a). With LC-MS, ESI and APCI 
has been implemented in analytical strategies in many application areas, e.g. 
environmental analysis, drug development within the pharmaceutical industry, 
characterisation of natural products and the characterisation of biomolecules like 
peptides, proteins, oligosaccharides etc.  
 
The selection of the appropriate HPLC conditions, whether reversed-phase liquid 
chromatography, ion-pairing chromatography, capillary electrophoresis or ion 
chromatography, and ionisation mode, ESI or APCI, depends upon the polarity of 
the analyte. ESI is best applied to the highly polar nature of the analyte and APCI 
ionises most efficiently compounds with low to moderately high polarities and in 
this respect is complementary to electrospray, which gives the best sensitivity for 
ionic compounds. Both interfaces ESI and APCI can be operated in positive and 
negative ion mode. Often, an appropriate selection for a given analyte can be 
made by considering that ESI transfers ions from solution into the gas phase, 
whereas APCI ionizes in the gas phase. As a rule of thumb, analytes occurring, 
as ions in solution may be best analysed by ESI, while non-ionic analytes may 
be well suited for APCI. 
 
As for the detection principles discussed above, all of these contribute 
significantly to the present-day success of hyphenation in HPLC. There is no 
doubt that, also today HPLC-photodiode-array (PDA) UV plays an important role 
(detection and peak-purity) in many research and development studies, and for a 
wide variety of routine analyses.  
 
Since the first description of gas-liquid chromatography in 1952, (James & 
Martin, 1952), gas chromatography (GC), besides its own technical development 
and the development of separation methods as a scientific discipline has been 
used to solve a large number of significant problems in various branches of 
science. 
 
GC has found an impressive number of industrial applications and the potential 
to be a powerful tool in routine analytical laboratories by increasing sample 
throughput and improving laboratory efficiency. Essential oil samples are  
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amongst the most complex samples known to analytical chemists. They contain 
a very large number of saturated and unsaturated alkanes, cyclic alkanes, 
aromatics and heteroatom-containing compounds. Therefore, GC 
technique/methods are very useful in the determination of essential oils, and 
offer a significant improvement in sensitivity over previous methods used for 
essential oils. 
 
2.1  Chromatographic system suitability parameter 
 
The quality of HPLC data collected begins with a well-behaved chromatographic 
system. System suitability specifications and tests are parameters that provide 
assistance in achieving this purpose. This section explains the terms used in 
HPLC assay development and method validation in this research. 
 
Capacity factor (k′): The capacity factor (occasionally called retention factor) is a 
measure of where the peak of interest is located with respect to the void volume, 
i.e., elution time of the non-retained components. The peak should be well 
resolved from other peaks and the void volume. Generally the value of k is > 2 
[4, appendix I], (Shabir & Arain, 2007b). 
 
K′ = (tR  –  t0) / t0   (1) 
 
where t0 is elution time of the void volume of non-retained components and tR is 
the retention time of the analyte. 
 
Resolution (Rs):  Rs  is a measure of how well two peaks are separated. For 
reliable quantitation, well-separated peaks are essential for quantitation. This is a 
very useful parameter if potential interference peaks may be of concern. The 
potential peak eluting closest to the main analyte peak of interest should be 
selected. Rs is minimally influenced by the ratio of the two compounds being 
measured. Rs of > 2 between the peak of interest and the closest potentially 
interfering peak (impurity, excipient, degradation product, internal standard, etc.) 
is desirable (USP, 2007). 
 
Rs  =   2 (tR2  -  tR1) / (w2  +  w1)   (2)  
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where tw is peak width measured at baseline of the extrapolated straight sides to 
baseline. 
 
Relative retention or selectivity (α): Relative retention (also called selectivity or 
separation factor α value) is a measure of the relative location of two peaks. This 
is not an essential parameter as long as the resolution (Rs) is stated. 
 
α = k2 / k1   (3) 
 
Tailing factor (T): The accuracy of quantitation decreases with increase in peak 
tailing because of the difficulties encountered by the integrator in determining 
where/when the peak ends and hence the calculation of the area under the peak. 
Integrator variables are pre-set by the analyst for optimum calculation of the area 
for the peak of interest. The acceptance criteria are that: T of ≤ 2 (USP, 2007). 
 
T  =  Wx / 2f   (4) 
 
where Wx is width of the peak determined at either 5% (0.05) or 10% (0.10) from 
the baseline of  the peak height. f is distance between peak maximum and peak 
front at Wx 
 
Theoretical plate number (N): N is a measure of column efficiency, that is, how 
many peaks can be located per unit run-time of the chromatogram.  
 
N  = 16 (tR / tw)
2   =  L / H   (5) 
 
N is fairly constant for each peak on a chromatogram with a fixed set of 
operating conditions. H, or the height equivalent of a theoretical plate (HETP), 
measures the column efficiency per unit length (L) of the column. Parameters, 
which can affect N or H, include peak position in the chromatogram particle size 
of stationary phase packing, flow-rate of mobile phase, column temperature, 
viscosity of mobile phase, and molecular weight of the analyte. The theoretical 
plate number depends on the elution time but in general should be > 2000 [USP, 
2007, 4, appendix I]. 
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3  Validation of a Reversed-phase HPLC Method 
for 1,10-Phenanthroline-5,6-Dione and Analysis of 
Its Impurities by HPLC–MS  
 
 
Method development is not always a simple task since there are a substantial 
number of parameters in HPLC and LC-MS, which may influence the final 
results, that are obtained. This is especially the case, when a required method 
does not exist in the literature and it is then that the analyst needs advanced 
knowledge and experience on both the analytical equipment and drug 
substance, or drug product that needs to be analysed. In this situation, applying 
the systematic approach discussed previously (Chapter 1, Figure 1.1) can make 
the task simpler and reduce the resources that the company needs to apply to 
the tasks.  
 
Using this philosophy, a new assay method was developed and validated for 
1,10-phenanthroline-5,6-dione [5, appendix I] which is a useful class of 
heterocyclic o-quinone compounds (Figure 3.1).  
 
 
NN
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N
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N
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H
O O
HO2C
CO2H
HO2C
IV  
Figure 3.1 - Heterocyclic o-quinone compounds: (I) 1,10-phenanthroline-5,6-dione; (II) 1,7-
phenanthroline-5,6-dione; (III) 4,7-phenanthroline-5,6-dione; (IV) pyrroloquinoline quinine. 
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The compound 1,10-phenanthroline-5,6-dione had been synthesized via two 
synthetic routes and its purity profile was determined.  Impurity profiling is an 
important issue in pharmaceutical analysis, particularly during product 
development and quality control. The standard requirements of such an impurity 
method are that all likely synthetic and degradative impurities are resolved from 
each other and the main drugs and that the impurities can be monitored at the 
0.1% (w/w) level or below. 
  
Application of the method in LC-MS mode resulted in the identification of 4,5-
diazafluoren-9-one (V) as the major impurity in 1,10-phenanthroline-5,6-dione   
prepared via the one-step oxidation of 1,10-phenanthroline. In contrast, the 
impurity (V) was absent from samples of 1,10-phenanthroline-5,6-dione 
produced using a three-step cobalt complexation route from 1,10-phenanthroline. 
As such, this latter method was preferred for the synthesis of high purity samples 
of 1,10-phenanthroline-5,6-dione. The comparison of two synthetic routes helped 
to identify the one yielding the best quality product. This approach of 
investigating the synthetic studies, analysis, impurity profiling and validating the 
method could also be applied to other similar compounds. 
 
The main interest was to prepare 1,10-phenanthroline-5,6-dione by the two main 
synthetic routes and identifying any impurities, where possible, to evaluate its 
suitability for use as a mediator to nicotinamide adenine dinucleotide (NADH) in 
biosensors for diabetics. A number of potential impurities were expected from an 
examination of the literature concerning the reactivity of the phenanthroline-5,6-
dione. Thus, compound (I) was known to undergo alkaline decarboxylation to 
afford 4,5-diazafluoren-9-one (V). Here, (V) may be obtained during the 
neutralisation of highly acidic reaction mixtures in the preparation of 1,10-
phenanthroline-5,6-dione. The use of KBr/HNO3/H2SO4 reaction medium may 
result in the formation of 5-bromo-1,10-phenanthroline (VI) and 5-nitro-1,10-
phenanthroline (VII) as by-products. Under certain oxidation conditions, the 1,10-
isomer (I) can be converted to 2,2’-bipyridine-3,3’-dicarboxylic acid (VIII) or 1h-
cyclopenta[2,1-b:3,4-b’]dipyridine-2-5-dione (IX) as reported (Figure 3.2). The 
scheme 1 shows the synthesis and the structures are shown in Figure 3.2. 
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Scheme 1 - Synthesis of 1,10-phenanthroline-5,6-dione. 
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Figure 3.2 – Chemical structure of potential impurities in 1,10-phenanthroline-5,6-dione: (V) 4,5-
diazafluoren-9-one; (VI) 5-bromo-1,10-phenanthroline; (VII) 5-nitro-1,10-phenanthroline; (VIII) 
2,2’-bipyridine-3,3’-dicarboxylic acid; (IX) 1h-cyclopenta[2,1-b:3,4-b’]dipyridine-2-5-dione. 
 
 
3.1  Step-by-step new method development by HPLC 
 
A project charter/plan was written for the feasibility, research and development 
study.  In the feasibility study, an assessment was made as to whether the 
assigned task could be successfully accomplished by using available resources. 
In the research phase, new knowledge was discovered on the compound in the 
hope that such information would be useful in developing a new method. The 
knowledge gained from the research phase was the physiochemical properties of 
the compound such as structure, solubility/stability in different solutions, pKa 
values, spectra (UV, MS, NMR), the synthetic routes, synthetic impurities, and  
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literature review documenting the analysis of similar compounds if any. This 
knowledge was used to develop a new method for 1,10-phenanthroline-5,6-dione 
compound. 
Good separation of 1,10-phenanthroline-5,6-dione from its synthetic impurities 
was achieved as demonstrated by the chromatogram displayed in Figure 3.3. 
The chromatographic run yielded four major peaks that are detailed as an area 
percent in Table 3.1. The first two peaks (at 2.07 and 2.37 min) are minor 
impurities and the third (3.74 min) is a major impurity. The peak at 2.75 min is 
the 1,10-phenanthroline-5,6-dione. The UV spectra of the potential impurities 
and 1,10-phenanthroline-5,6-dione are shown in Figure 3.4. Here, the data is 
from the analysis of a sample of crude (I) derived from the one-step oxidation of 
1,10-phenanthroline.  
 
Table 3.1 - Chromatographic results of 1,10-phenanthroline-5,6-dione and its impurities 
Compound  Retention time (min)  Area (µV)  Area (%) 
Impurity  (1)  2.07  25404  0.64 
Impurity (2)  2.37  23658  0.59 
1,10-phenanthroline-5,6-dione 2.75  3725059  93.21 
Impurity (3)  3.74  107954  2.70 
 
The analytical conditions chosen during method development were then 
optimised to further improve to gain greater confidence on the generation of 
analytical data. After the optimisation phase, pre-validation characteristics such 
as robustness, stability of analytical solutions, linearity, precision, specificity and 
system suitability were studied [5, appendix I]. 
 
System suitability testing was performed to determine the accuracy and precision 
of the system by injecting six injections of a solution containing 0.6 mg 1,10-
phenanthroline-5,6-dione/mL. All peaks were well resolved and the precision of 
injections for all peaks was acceptable. The percent relative standard deviation 
(%RSD) of the peak area responses was measured. The % RSD of peak areas 
was average 0.62 (n = 6) the tailing factor (T) for each peak of 1,10-
phenanthroline-5,6-dione was 1.61 and theoretical plate number ( N ) was 3035. 
The resolution between each peak were > 1.2, and retention time (RT) variation 
RSD ≤ 2% for six injections. 
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Figure 3.3 – Separation of crude 1,10-phenanthroline-5,6-dione displaying its impurities. This 
material was produced via the one-step oxidation method and was not crystallised. Conditions: 
isocratic elution with methanol/water (50/50, v/v) with 0.1% of triethylamine, flow rate 0.8 
mL/min, Luna C18 column (150 x 4.60 mm, 5-µm particle size), temperature 40°C, injection 
volume 2µl, UV detection 254 nm. 
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Figure 3.4 - PDA UV match spectra of the middle of the peak corresponding to the retention 
time of the main component of 1,10 phenanthroline-5,6-dione and a reference sample.  
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For the assessment of method robustness, a number of chromatographic 
parameters were investigated such as flow rate (± 0.2 mL/min), column 
temperature (± 5°C), mobile phase composition (± 5% organic) and wavelength 
(± 5 nm). In all cases, good separation were always achieved, indicated that the 
method remained selective for all components under the developed conditions. 
 
3.2  Identification of impurities by LC-MS 
 
It was not possible to identify the chemical structure of the impurities by 
HPLC/PDA UV alone. For this purpose, LC-MS was selected to obtain structural 
information. The full scan LC-MS spectra of 1,10-phenanthroline-5,6-dione and 
its impurities were measured in the mass range m/z 100-650. 1,10-
Phenanthroline-5,6-dione displayed a single peak at 2.75 min with a 
corresponding protonated molecular ion of mass m/z 211.2. Impurity peak 3 at 
3.74 min was assigned to 4,5-diazafluoren-9-one (V) on the basis of both HPLC 
(Figure 3.5) data and MS (Figure 3.6). Again, a protonated molecular ion of mass 
m/z 183.3 was observed in the mass spectrum.  
 
The chemical structure of impurities 1 and 2 could not be identified from the 
HPLC and LC-MS data. However, the ions at m/z 183.3 and 241.2 for the two 
impurities (2.07 and 2.37 min) did not correspond with the other suspected 
impurities such as 1,10-phenanthroline, 5-bromo-1,0-phenanthroline (VI), 5-nitro-
1,10-phenanthroline (VII), 2,2’-bipyridine-3,3’-dicarboxylic acid (VIII) or 1h-
cyclopenta[2,1-b:3,4-b’]dipyridine-2-5-dione (IX). This was a first report for an 
HPLC purity assay on this important compound in the scientific literature. 
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Figure 3.5 - Separation of 4,5-diazafluoren-9-one (V), (impurity 3). Conditions: isocratic elution 
with methanol/water (50/50, v/v) with 0.1% of triethylamine, flow rate 0.8 mL/min, Luna column 
C18 (150 x 4.60 mm, 5-µm particle size), temperature 40°C, injection volume 2µL, UV detection 
254 nm. 
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Figure 3.6 - Mass spectra (x-axis: relative abundance) of 1,10-phenanthroline-5,6-dione and its 
impurities 1-3. Conditions: ESI+, source temperature 100°C, capillary voltage 3.0 kV, cone 
voltage 30V.  
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3.3  Step-by-step method validation  
 
The first step in test method validation was the characterisation phase. Initially a 
cross-functional team (CFT) was assembled. In this phase, the validation 
performance characteristics were chosen for the assay method type. The 
validation performance characteristics were linearity, range, intermediate 
precision, repeatability, accuracy and specificity studied. 
 
For best practice, the characterisation protocol was written, approved and 
executed using validated equipment under highly GMP/GLP environment. Limits 
were set based on internal use purposes only and not for regulatory compliance 
of this analytical method. All personnel involved in the characterisation protocol 
activities were trained on characterisation protocol, equipment and test method 
prior to performing their functions. On completion of the characterisation study, 
the results/data were critically assessed from a statistical point of view. Finally, a 
validation step-by-step protocol was written and approved by the CFT and 
executed.  
 
As has been indicated, great care was taken in the method development phase, 
which resulted in the subsequent validation being straightforward.  
 
The linearity was studied over two days using six different amounts of 1,10-
phenanthroline-5,6-dione in the range of 0.04 -1.60 mg/mL. The regression 
coefficient obtained (r
2: 0.9998 day 1, 0.9996 day 2), demonstrated the excellent 
relationship between peak area and the concentration of 1,10-phenanthroline-
5,6-dione (Table 3.2).  
 
Accuracy (percent recovery) study was investigated, five different solutions (10, 
20, 40, 100 and 160% of target) were prepared with a known added amount of 
dione  I and injected in triplicate. Percent recoveries of response factor 
(area/concentration) were calculated. Excellent recoveries were obtained 
averaged 99.9%. 
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Table 3.2 - Linearity assessment of the HPLC method for the assay of 1,10-phenanthroline-
5.6-dione 
Concentration 
(mg/mL) 
Concentration (as 
%) of 0.6 mg/mL 
Area (µV) as mean of 3 
injections  (day 1) 
Area (µV) as mean of 2 
injections  (day 2) 
0.0400 4.0  225761  241740 
0.1000 10  577405  616281 
0.2002 20  1126188  1401765 
0.4004 40  2574365  3063222 
1.0009 100  6561498  8541076 
1.6016 160  10458276 13686533 
Correlation coefficient:  0.9998  0.9996 
Equation for regression line:  y = 7E+06x - 90335  y = 9E+06x - 263239 
 
 
The PDA three-dimensional chromatogram demonstrated [5, appendix I] a good 
separation of the 1,10-phenanthroline-5,6-dione peak (c) (retention time 2.5 min) 
and from the impurities (retention time 1.4 and 2.0 min) and of the impurities 
from each other. A wavelength of 254 nm was found to be the most effective 
compromise to accomplish the detection and quantification of the two impurities 
and the main 1,10-phenanthroline-5,6-dione component in a single run. The 
impurities and the 1,10-phenanthroline-5,6-dione peaks were adequately 
resolved from each other; typical resolution values for the 1,10-phenanthroline-
5,6-dione peak were greater than 1.5. This method possessed acceptable 
specificity. 
 
 
Table 3.3 - Assay percent results of 1,10-phenanthroline-5,6-dione under stress 
conditions 
Stress 
conditions 
Sample treatment  RT (min)  Assay (%)  Area (µV) 
Reference Fresh  solution  2.35  99.91  8582691 
Acid  1N HCl for 24 hour  2.30  99.94  8753142 
Base  1N NaOH for 4 hour  2.35  99.50  8697192 
Heat  50°C for 1 hour  2.35 99.80  8630907 
Light  UV Light for 24 hour  2.30  99.25  7189035 
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Forced degradation studies were also performed to evaluate the specificity with 
respect to 1,10-phenanthroline-5,6-dione and its impurities under four stress 
conditions (heat, UV light, acid, base). Solutions of 1,10-phenanthroline-5,6-
dione were exposed to 50°C for 1h, UV light using a Mineralight UVGL-58 for 
24h, acid (1M HCl) for 24h, and base (1M NaOH) for 4h. Summary data of the 
stress results is shown in Table 3.3. It is evident from Figure 3.3 that the method 
had been able to separate the peaks of the degraded products from that of the 
1,10-phenanthroline-5,6-dione. This was further confirmed by peak purity 
analysis on a PDA UV detector. 
 
The precision of the chromatographic method was investigated by measuring the 
repeatability on ten replicate injections at 100% test concentration (0.6 mg/mL) 
and inter day variation on injecting  (n = 10) the same solution (day 2). The 
relative standard deviation (RSD) value for repeatability was 0.04% and inter day 
variation was 0.44%, and illustrated excellent precision for this LC assay method. 
The excellent results obtained due to the care taken during research phase. 
 
Upon successfully completing the validation, the data was statistically analysed 
against its acceptance criteria by the statistician in order to test its validity. The 
validated method was then used routinely in the development laboratory for 1,10-
phenanthroline-5,6-dione compound and its impurities. 
 
3.4 Conclusion 
 
A reversed-phase HPLC method for the assay and purity evaluation of 1,10-
phenanthroline-5,6-dione obtained via two synthetic routes was developed using 
a systematic approach. Application of the method in LC-MS mode resulted in the 
identification of 4,5-diazafluoren-9-one (V) as the major impurity in 1,10-
phenanthroline-5,6-dione prepared via the one-step oxidation of 1,10-
phenanthroline. The research methodology was validated for its validity using 
validated equipment under a highly GLP/GMP regulated environment. The 
validation study showed excellent results of the careful step-by-step approach 
that had been followed.  The method was precise with RSD ≤ 0.44% for intera 
and interday precision, and accurate with recoveries in between 99.76-100.00%. 
After the validation, the applicability of the method for determination and  
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identification of 1,10-phenanthroline-5,6-dione was demonstrated and adopted 
for routine use through Abbott. 
 
This research has made a significant and coherent contribution to new 
knowledge including new HPLC and LC-MS method; combined use of 
photodiode array UV and LC-MS to identify unknown impurities; newly identified 
information on 1,10-phenanthroline-5,6-dione impurities profile; newly identified 
detailed information on comparison of syntheses; a more detailed step-by-step 
approach to method development and validation and a robust validated method. 
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4  Development and Validation of a HPLC Method 
for 4,7-Phenanthroline-5,6-Dione and 
Identification of Its Major Impurity by HPLC–MS–
APCI 
 
 
In a similar to that described previously for 1,10-phenanthroline-5,6-dione 
manner (Chapter 3) a new purity assay for 4,7-phenanthroline-5,6-dione 2 was 
developed and validated [6, appendix I] by HPLC. Impurity was investigated 
using LC-MS with atmospheric-pressure chemical ionization and photodiode-
array UV detection. 
 
4,7-Phenanthroline-5,6-dione is an important heterocyclic quinone, which is 
known historically to be active against protozoa, amoebae and bacteria 
(Kradolfer, et al., 1960). The compound has recently been suggested to be of 
use in the prevention and treatment of Alzheimer’s (Xilinas & Gerolymatos, 
2000), macular degenerative (Xilinas, 2002) and prion (Xilinas, & Hannoun, 
2002) diseases. 4,7-Phenanthroline-5,6-dione  is a starting material for 
phenanthroline ligands (Imor et al.,1996), which are useful for the preparation of 
complexes of transition metals, particularly ruthenium (D’Alessandro et al., 
2001). The quinone cofactor methoxatin can be replaced by in glucose 
dehydrogenase while maintaining enzyme activity. The interest in (2) stems from 
its possible use biosensor electrodes as a redox mediator for the cofactor NADH 
(Itoh et al.,1992). 
 
A simple method was sought for the synthesis of (2), which was reportedly 
available via 5-methoxy-4,7-phenanthroline itself derived from a double Skraup 
reaction of 2-methoxy-1,4-phenylenediamine hydrosulphate or its diacetyl 
derivative (Figure 4.1).  
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NH3
+ HSO4
- NH2
OCH3
(i)
N N
OCH3
(ii)
N N
O O
(iii)
N N
NN
4
3
1 2  
 
(i) Glycerol  (C3H8O3), sulfuric acid, sodium m-nitrobenzene sulfonate (C6H4NO5SNa) 
(ii)  Sulfuric acid (H2SO4), nitric acid (HNO3) 
(iii)  Ethylene diamine (H2NCH2CH2NH2), methanol (MeOH) 
  
 
Figure 4.1. Synthesis of phanquone: (1) 4,7-Phenanthrolino-5,6:5',6'-pyrazine; (2) 4,7-
Phenanthroline-5,6-dione; (3) 5-Methoxy-4,7-phenanthroline; (4) 2-Methoxy-1 ,4-
phenylenediamine hydrosulfate. 
 
 
Avoiding the notorious Skraup synthesis, it was possible to the commercially 
available 4,7-phenanthroline to (2) using oxidation conditions previously applied 
to the 1,10-isomer (Hiort et al., 1993; Calderazzo et al., 1999; Mlochowski, 1974) 
(Figure 4.2).  However, it had been suspected that the use of KBr/HNO3/H2SO4 
would result in the formation of brominated 4,7-phenanthrolines as by-products.  
 
N N
O O
NN
KBr, HNO3
H2SO4
 
 
Figure 4.2 - Synthesis of 4,7-phenanthroline-5,6-dione. 
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4.1 Related  substances   
 
The quantity of each impurity peak (the known impurity designated as peak b 
plus any other impurity peak) is calculated as an area percent versus the total 
area of all peaks in the chromatogram. Each impurity peak, plus the total area 
percent of all impurity peaks, must fall within the requirements in the specification 
(Table 4.1). 
 
 
Table 4.1 - Limits for chromatographic purity of 4,7-phenanthroline-5,6-dione and its 
impurity 
Parameter Assay  Related  substances 
Peak assignment  1(a)
* 2(b)
* 
Retention time (min)  5.16  6.90 
Limit as percent total area  c ≥ 96.0%  ≤ 2.0% b + all other impurities. 
No other peak area can exceed 2.0% 
* a, 4,7-Phenanthroline-5,6-dione (1); b, impurity 1 
 
 
4.2  Assay and purity calculations 
 
The area percent of main 4,7-phenanthroline-5,6-dione peak (designated as 
peak a) is determined as for the impurities. The area percent must fall within the 
specifications (Table 4.1). The purity of the 4,7-phenanthroline-5,6-dione drug 
substance is calculated in relation to the reference standard using the area of the 
main peak a: 
 
 
 
 
 
 
 
 
 
 
Percent purity =  
 mg / 100 mL of standard x total area of peak a from sample  
area of peak a from standard x mg / 100 mL of sample   
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4.3  Separation of 4,7-phenanthroline-5,6-dione and its impurity 
 
The analytical method was developed using systematic step-by-step approach 
as previously described in Chapter 3. Good separation and high sensitivity was 
achieved by using acetonitrile containing 10 mM potassium dihydrogen 
phosphate containing 0.1% triethylamine as the mobile phase with varying 
detection wavelengths, based on the response of the main component. The main 
peak tailed badly on some C18 columns with these mobile phases but adding 
triethylamine minimised this. Amines such as triethylamine are often added in the 
mobile phase to reduce peak tailing caused by the strong intraction of basic 
analytes with the acidic surface silanols. The amount of organic modifier was 
adjusted so that the assay run time could be reduced for faster analysis of the (2) 
samples. A chromatogram illustrating the separation of (2) and the one potential 
impurity is illustrated in Figure 4.3 confirming specificity with respect to (2).  
 
 
 
Figure 4.3 - Separation of 4,7-phenanthroline-5,6-dione (retention time 5.16 min) displaying its 
impurity (retention time 6.90 min). Conditions: isocratic elution with aqueous solution of 10 mM 
phosphate buffer (pH 3.05)/acetonitrile (85/15, v/v) containing 0.1% triethylamine, XTerra RP-18 
column (150 x 4.6 mm, 5-µm particle size), flow rate 0.5 mL/min, injection volume 2 µL, column 
temperature 40°C, UV wavelength 254 nm.  
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The remaining chromatographic conditions listed in HPLC experimental section 
were chosen for the following reasons: the lower flow rate of 0.5 mL/min was 
chosen because of the potential problems associated with elevated back 
pressures. The photodiode-array detector (UV) was set at 254 nm. 
 
During method development phase, great care was taken to develop a robust 
method. A number of chromatographic parameters were investigated. The 
column temperature was held at 40°C although separations at 30°C and 35°C 
indicated that slight variations in temperature did not have a significant effect on 
retention, resolution or peak shape. The injection volume of 2 µL and sample 
concentration of 0.40 mg 4,7-phenanthroline-5,6-dione per mL in the mobile 
phase were chosen to simplify sample preparation. This concentration of (2) 
allowed both assay (of the main component) and purity evaluation (of trace 
impurity). At this concentration, the (2) peak is well within the linear range for UV 
detection, and trace components were readily detectable. 
 
System suitability testing was performed to determine the accuracy and precision 
of the system by making six injections of a solution containing 0.40 mg of 4,7-
phenanthroline-5,6-dione per mL. All peaks were well resolved and the precision 
of injections for all peaks was acceptable. The RSD of peak areas averaged 
0.30% (n = 6); the tailing factor (T) for each peak of (2) was 1.12 and theoretical 
plate number (N) was 3240. The resolution between each peak were > 2.40, and 
retention time variation RSD 0.3% for six replicate injections. 
 
For the assessment of method robustness, a number of chromatographic 
parameters were investigated such as flow rate (± 0.2 mL/min), column 
temperature (± 5°C), mobile phase composition (± 5% organic, ± 5 mM buffer 
concentration), pH (0.2 unit) and wavelength (± 5 nm). In all cases, good 
separation were always achieved, indicated that the method remained selective 
for all components under the developed conditions. 
 
4.4  Identification of impurities by LC-MS 
 
Two major peaks are shown in the chromatogram in Figure 4.3. The first peak at 
5.16 min (98.93 area %) was due to 4,7-phenanthroline-5,6-dione. The second  
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peak at 6.90 min (0.81 area %) was thought to be a brominated impurity.   
Elemental analysis of some (2) samples demonstrated the presence of ca. 0.3% 
Br. These samples had been produced via direct oxidation of 4,7-phenanthroline 
with KBr/HNO3/H2SO4. In contrast, a sample of (2) prepared via 5-methoxy-4,7-
phenanthroline was bromine-free. Consequently, a standard sample of 5-bromo-
4,7-phenanthroline, the chromatogram in Figure 4.4, was prepared by a literature 
procedure (Mlochowski, 1974). 
 
It was not possible to identify the chemical structure of this impurity by HPLC with 
PDA UV detection. For this purpose, LC-MS was selected. The full scan LC-MS 
spectra of 4,7-phenanthroline-5,6-dione and its impurity were measured in the 
mass range m/z 100-650. The compound (2) displayed a single peak at 5.16 
min, which corresponded to the molecular mass at m/z 209.99 and an impurity 
peak (6.90 min) at m/z 258.88. The mass spectra of each peak ion 
chromatogram are shown in Figures 4.5 and 4.6 respectively. The impurity peak 
b at 6.90 min was identified as 5-bromo-4,7-phenanthroline, by both HPLC and 
MS data, with the [M + H]
+ ion pair at m/z 258.88 and 260.86 (Figure 4.6) being 
consistent with the presence of bromine due to the known 1:1 isotope cluster for 
79Br and 
81Br. It is interesting to note that the (2) displayed an M
+ ion rather than 
an [M + H]
+ ion as previously found for its 1,10-isomer and, indeed, the bromo 
compound above. The reason for this difference was unknown but the result was 
reproducible since external mass spectral analysis (EI, positive mode) also 
yielded an M
+ ion for the (2). 
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Figure 4.4 - Separation of 5-bromo-4,7-phenanthroline (impurity). Conditions: isocratic elution 
with aqueous solution of 10 mM phosphate buffer (pH 3.05)/acetonitrile (85/15, v/v) containing 
0.1% triethylamine, XTerra RP-18 column (150 x 4.6 mm, 5-µm particle size), flow rate 0.5 
mL/min, injection volume 2 µL, column temperature 40°C, UV wavelength 254 nm. 
 
 
 
 
 
Figure 4.5 - Mass spectrum of 4,7-phenanthroline,5-6-dione. Conditions: XTerra MS C18 column 
(50 x 2.1 mm, 3.5-µm particle size), mobile phase 10 mM ammonium acetate/acetonitrile (90/10, 
v/v), injection volume 2 µL, APCI positive ionization mode, source temperature 120°C, capillary 
voltage 3.0 kV, Cone voltage 50V, cone gas flow, 100 l/h, APCI probe temperature 500°C, UV 
wavelength 210 to 400 nm. 
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Figure 4.6 - Mass spectrum of main impurity of 5-bromo-4,7-phenanthroline. See Figure 4.5 for 
LC-MS conditions. 
 
 
4.5 Step-by-step method validation 
 
The analytical method validation was carried out using systematic step-by-step 
approach as previously described in Chapter 3. 
 
The linearity was studied in the concentration range 0.05 to 1.50 mg/mL. Six 
solutions were prepared corresponding to 0.05, 0.25, 0.50, 0.75, 1.00 and 1.50 
% of the nominal analytical concentration (0.40 mg/mL) and the following 
regression equation was found by plotting the peak area (y) versus the 4,7-
phenanthroline-5,6-dione concentration (x) expressed in mg/mL: y = 221070x + 
116721 (r
2 = 0.9991). The analyte response was linear across 80-120% of the 
target 4,7-phenanthroline-5,6-dione concentration. 
 
The limit of detection (LOD) and limit of quantification (LOQ) tests for the 
procedure were performed on samples containing very low concentrations of 
analyte. For this method, LOD was 2.0 and the LOQ was 50 µg/mL and RSD 
0.50% (n = 3).  
 
The precision of the chromatographic method was investigated by measuring 
repeatability on six replicate injections at 100% test concentration (0.40 mg/mL)  
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and intermediate precision on three replicate injections at three different 
concentrations (0.05, 0.50 and 1.50 mg/mL). The RSD values were ≤ 0.30% in 
all cases and illustrated excellent precision for this method. 
 
Accuracy was studied by preparing different solutions with a known added 
amount of (2) at three different concentrations (0.05, 0.50 and 1.50 mg/mL) and 
injected in triplicate. Mean recoveries for sample was found to be 99.0%. 
 
The PDA three-dimensional chromatogram [6] demonstrated a good separation 
of the (2) peak a (RT = 5.16 min) and the impurity (RT = 6.90 min) from each 
other. A wavelength of 254 nm was found to be the most effective compromise to 
accomplish the detection and quantification of all impurities and the main 
component of (2) in a single run. The impurity and (2) peak area were 
adequately resolved from each other; typical resolution values for the (2) peak 
were greater than 2.39. This method demonstrated acceptable specificity.  
 
Forced degradation studies were performed to evaluate the specificity of (2) and 
its impurity under four stress conditions (heat, UV light, acid, base). Solutions of 
(2) were exposed to 50°C for 1h, UV light using a Mineralight UVGL-58 light for 
24h, acid (1M HCl) for 24h and base (1M NaOH) for 4h. In all cases, peak area 
was >99%. It is evident from Figure 4.3 that the method had been able to 
separate the peaks due to the degraded products from that of the (2). This was 
further confirmed by peak purity analysis on a PDA UV detector. 
 
4.6 Conclusion 
 
A new reversed-phase HPLC method for the identity, assay and purity evaluation 
of 4,7-phenanthroline-5,6-dione and its synthetic impurities had been 
successfully developed. 5-Bromo-4,7-phenanthroline was identified as main 
impurity by applying the method in LC-MS with photodiode-array UV detection. 
This impurity was only present in 4,7-phenanthroline-5,6-dione prepared via 
direct oxidation of 4,7-phenanthroline with KBr/HNO3/H2SO4. 4,7-Phenanthroline-
5,6-dione obtained via oxidation of 5-MeO-4,7-phenanthroline is bromine-free. 
Studies have demonstrated that the new assay method was rapid, simple, 
reliable and robust. It was extensively validated using validated LC-MS system.  
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Very good validation data was obtained and this was in no small part due to the 
thoroughness of the initial ‘research’ and the careful step-by-step approach that 
had been followed.  
 
This research has made a significant and coherent contribution to new 
knowledge including new validated HPLC and LC-MS method; combined use of 
PDA UV and LC-MS to identify unknown impurity; new information on 4,7-
phenanthroline-5,6-dione compound; newly identified information on 4,7-
phenanthroline-5,6-dione  impurities profile; newly investigated information on 
comparison of synthesis and a more detailed approach to method development 
and validation. 
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5  Determination of 2-(Diethylamino)-N-(2,6-
Diethylphenyl) Acetamide in a Gel Pharmaceutical 
Formulation by HPLC 
 
 
Best practice in method development and validation is equally important in the 
analysis of active components in formulated products. In this study [7, appendix 
I], a rapid, simple, reliable and robust HPLC assay method for determining the 
content of 2-(diethylamino)-N-(2,6-dimethylphenyl) acetamide  in a gel 
formulation was developed, validated and implemented to the quality control 
laboratory for bulk and final product release.  
 
2-(diethylamino)-N-(2,6-dimethylphenyl) acetamide (1) is widely used as a local 
anaesthetic that can be administered in a gel matrix (Stegman & 
Stoukides,1996).  It has also achieved prominence as antiarrhythmic agent and 
is now in common use particularly as emergency treatment for ventricular 
arrhythmias that are encountered after cardiac surgery or acute myocardial 
infection.  
 
2-(diethylamino)-N-(2,6-dimethylphenyl) acetamide (1)
H
N C
O
H2
C N (C2H5)2
H3C
H3C
.HCl.H2O
 
 
 
5.1  Step-by-step new method development  
 
A project charter/plan was written for the feasibility, research and development 
study.  In the feasibility study, an assessment was made as to whether the 
assigned task could be successfully accomplished by using available resources. 
In the research phase, new knowledge was discovered on the compound in the 
hope that such information would be useful in developing a new method. The  
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knowledge gained and received in the research phase was the physiochemical 
properties of the compound such as structure, solubility/stability in different 
solutions,  pKa values, spectra (UV, MS, NMR), any information regarding 
intended formulations, and literature review documenting the analysis of similar 
compounds. This information was used to develop a new method for 2-
(diethylamino)-N-(2,6-dimethylphenyl) acetamide  drug compound. 
 
The chromatographic analysis of 2-(diethylamino)-N-(2,6-dimethylphenyl) 
acetamide (pKa 7.86) was carried out in the isocratic mode using a mixture of 
53% acetonitrile in aqueous buffer pH 7.0 (53:47, v/v) as mobile phase. Diluting 
the standard and sample in buffer pH 7.0 gave solutions that could be injected 
directly (without further dilution, filtration or centrifugation). Chromatograms of 
the 2-(diethylamino)-N-(2,6-dimethylphenyl) acetamide gave good peak shape 
(Figure 5.1) and co-elution of excipients was not observed (Figure 5.2) at the 
same retention time. Importantly, following the adapted step-by-step philosophy, 
robustness studies including system suitability and stability of analytical solutions 
were also conducted during the method development phase. 
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Figure 5.1 – Separation of 2-(diethylamino)-N-(2,6 dimethylphenyl) acetamide. Conditions: 
isocratic elution with potassium phosphate buffer (pH 7.0)/acetonitrile (47/53, v/v), flow rate 2 
mL/min, injection volume 20 µL, UV wavelength 254 nm, C18 µ-Bondapak column 3.9 mm x 
300 mm, 5-µm particle size. 
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Figure 5.2 - Three-dimensional chromatogram of the mixture of 2-(diethylamino)-N-(2,6-
dimethylphenyl) acetamide. For experimental conditions see Figure 5.1. 
 
 
5.2  Step-by-step method validation 
 
Initially a cross-functional team (CFT) was assembled. As a best practice, the 
characterisation protocol was written, approved and executed using validated 
equipment. In this phase, the validation performance characteristics were chosen 
for the assay method type. The validation performance characteristics were 
linearity, range, intermediate precision, repeatability, accuracy and specificity. All 
personnel involved in the characterisation protocol activities were trained on 
characterisation protocol, equipment and test method prior to performing their 
functions. On completion of the characterisation study, the results/data were 
critically assessed from a statistical point of view. Then a method validation 
protocol was prepared in compliance with GMP/GLP and approved prior to its 
initiation for this formulated product.  
 
The linearity was studied using seven different amounts of 2-(diethylamino)-N-
(2,6-dimethylphenyl) acetamide in the range of 20-140% around the theoretical 
values (1.40 µg/mL), and the following equation was found by plotting peak area 
(y) versus concentration (x) expressed in µg/mL:  y = 1.30664e + 003x (r
2 = 
1.000). The excellent linearity was seen for this chromatographic assay method. 
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The precision of the method was investigated with respect to repeatability and 
intermediate precision.  Repeatability of the method was evaluated by assaying 
six replicate injections of the 2-(diethylamino)-N-(2,6-dimethylphenyl) acetamide 
at 100% of test concentration (1.4 µg/mL). The RSD of the retention time (min) 
was 0.01% and peak area was 0.18%. Intermediate precision was demonstrated 
by two analysts, using two HPLC systems and evaluating the relative peak area 
percent data across the two HPLC systems at three concentration levels (60, 
100 and 120%) that covered the assay method range (0.2-14 mg/mL). The RSD 
values for both HPLC systems and analysts ware less than 0.13%  (Table 5.1) 
and illustrated the excellent precision of the chromatographic method. 
 
 
Table 5.1 - Intermediate precision results of 2-(diethylamino)-N-(2,6-dimethylphenyl) 
acetamide 
  HPLC System1  HPLC System 2 
Sample S1 
(60%) 
S2 
(100%) 
S3 
(120%) 
S1 
(60%) 
S2 
(100%) 
S3 
(120%) 
Analyst 1  99.85  99.88  99.82  99.95  99.98  99. 97 
Analyst  2  99.89  99.85 99.80 99.92 99.96 99.98 
Mean  (HPLC)  99.87  99.86 99.81 99.94 99.97 99.98 
Mean  (Analyst)  99.90  99.93 99.90 99.91 99.90 99.89 
RSD (criteria ≤ 2%) 
HPLC1 & 2  
HPLC1 S1 + HPLC2 S1 = 0.05; HPLC1 S2 + HPLC2 S2 = 0.08; 
HPLC1 S3 + HPLC2 S3 = 0.12 
RSD (criteria ≤ 2%) 
Analysts 
HPLC1 S1 + HPLC2 S1 = 0.07; HPLC1 S2 + HPLC2 S2 = 0.02; 
HPLC1 S3 + HPLC2 S3 = 0.07 
 
 
Injections of the extracted placebo were performed to demonstrate the absence 
of interference with the elution of the 2-(diethylamino)-N-(2,6-dimethylphenyl) 
acetamide. The results demonstrate that there was no interference (Figure 5.3) 
from the other materials in the gel formulation, and therefore confirm the 
specificity of the method.  
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Figure 5.3 - Chromatogram of placebo demonstrating the absence of interference with the 
elution of 2-(diethylamino)-N-(2,6-dimethylphenyl) acetamide (retention time 2.0 min). 
Conditions: isocratic elution with potassium phosphate buffer (pH 7.0)/acetonitrile (47/53, v/v), 
flow rate 2 mL/min, injection volume 20 µL, UV wavelength 254 nm, C18 µ-Bondapak column 
(3.9 mm x 300 mm, 5-µm particle size). 
 
 
The accuracy (percent recovery) of the method was evaluated by adding known 
quantities of 2-(diethylamino)-N-(2,6-dimethylphenyl) acetamide in the gel 
formulation samples to give a range of 2-(diethylamino)-N-(2,6-dimethylphenyl) 
acetamide concentration of 75-150% (n = 3) of that in a test preparation. These 
solutions were analysed and the amount of analyte recovered calculated. The 
recovery data expressed as an average percent of triplicate injections are 
presented in Table 5.2 and showed excellent recoveries of active compound 
from gel formulation.  
 
Table 5.2 - Recovery results of 2-(diethylamino)-N-(2,6 dimethylphenyl) acetamide from 
samples with known concentration 
Amount of analyte (mg)   
Sample 
Percent of 
nominal  Added Recovered 
Recovery  
(%, n = 3) 
RSD  
(%, n = 3) 
1 75  1.70  1.704  100.23 0.13 
2 100  3.20  3.204  100.14 0.20 
3 150  5.10  5.097  99.95  0.15 
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The LOD and LOQ tests for the procedure were performed on samples 
containing very low concentrations of analyte. The LOD was (s/n ratio 3.2) 100 
ng/mL and the LOQ was (s/n ratio 10.2) 250 ng/mL and RSD 0.36% for three 
replicate injections. 
 
Upon successfully completing the validation, the data was statistically analysed 
against its acceptance criteria by the statistician in order to test its validity. The 
validated method was then implemented and used routinely in the quality control 
laboratory for products containing 2-(diethylamino)-N-(2,6-dimethylphenyl) 
acetamide compound for release. 
 
5.3 Conclusion 
 
A new HPLC method for the assay of 2-(diethylamino)-N-(2,6-dimethylphenyl) 
acetamide was developed and validated successfully using systematic approach. 
The results showed that the method was very selective no significant interfering 
peak was detected; accurate with the percentage recoveries of 99.95-100.23 and 
reproducible with the RSD of ≤ 0.20% in each case.  
 
The calibration curve was linear form 20-140% of the analytical concentration of 
1.4 µg/mL with excellent correlation coefficient of r
2 = 1.0000. The method was 
sensitive as little as 100 ng/mL can be detected with the quantitation limit of 250 
ng/mL. This excellent validation data did not arise by chance, but because 
validation was borne in mind during the method research and development 
phase. For example, then paraphrase the slot section “preliminary precision, 
linearity and robustness studies performed during the development phase that 
could be injected directly”. The method was transferred and used in the quality 
control laboratory for analysis of 2-(diethylamino)-N-(2,6-dimethylphenyl) 
acetamide in bulk, raw materials and final gel product for final release.  
 
This research has made a significant and coherent contribution to new 
knowledge about the product, including more detailed step-by-step approach to 
method validation and also a very well validated (under GMP/GLP 
considerations) assay method. 
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6 Determination  of  Combined  p-Hydroxy Benzoic 
Acid Preservatives in a Liquid Pharmaceutical 
Formulation by HPLC  
 
 
The determination of excipients in a formulation can also be important and 
provide a difficult challenge to analytical scientists. For this case [8, appendix I], 
the individual contents of three p-hydroxy benzoic acid ester preservatives in a 
complex multi-component solution were determined following the development 
and validation of an HPLC method. The results / data generated from these new 
validated assay methods were submitted to the regulatory agency for product 
licence for marketing authorisation. The results were critically reviewed by the 
regulatory agency for its reliability, validity and approved for product licence. 
Thereafter, this assay method was implemented to the quality control laboratory 
and applied for the quantification and a stability study of all the compounds in the 
liquid pharmaceutical formulation for bulk, intermediate and final product release.  
 
Combined p-hydroxy benzoic acid preservative is a combination of three esters 
including methyl hydroxybenzoate (methylparaben, MP), ethyl hydroxybenzoate 
(ethylparaben, EP) and propyl hydroxybenzoate (propylparaben, PP) (Figure 
6.1). Its theoretical composition is given in Table 6.1. Each of these 
preservatives have been widely used as antimicrobial and anti-fungal agents in 
food, beverages, cosmetics and pharmaceuticals (Kang & Kim, 1997) because of 
their broad antimicrobial spectrum with good stability and non-volatility (Society 
of Japanese Pharmacopoeia, 1984). Hence, the simultaneous determination of 
these preservatives in commercial pharmaceutical products is particularly 
important both for quality assurance and consumer safety. 
 
Table 6.1 - Theoretical composition of combined p-hydroxy benzoic acid 
Component  Theoretical composition (%) 
Methyl hydroxy benzoate  73.21 
Ethyl hydroxy benzoate  16.07 
Propyl hydroxy benzoate  10.71 
Total 99.99 
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Figure 6.1 - Structures of the analytes, in order of elution: (1) methylparaben; (2) ethylparaben; 
(3) propylparaben. 
 
 
6.1 Step-by-step new method development  
 
A similar systematic strategy was used in developing a new method for 
combined p-hydroxy benzoic acid as discussed in Chapter 5. Initially, different 
chromatographic conditions were investigated to achieve best separation. Using 
optimised conditions the chromatographic analysis of combined p-hydroxy 
benzoic acid (pKa ∼8.4) was carried out in the isocratic mode using a mixture of 
52.5% methanol in potassium phosphate buffer pH 7.05 ± 0.05 (52.5:47.5, v/v) 
as mobile phase. 20 µL of standard and sample solutions were injected 
automatically into the column. Subsequently, the liquid chromatographic 
behaviours of both drugs were monitored with a UV detector at 254 nm. 
Additionally, preliminary system suitability, precision, linearity and robustness 
studies performed during the development phase of the method showed that the 
20 µL injection volume was reproducible and the peak response was significant 
at the analytical concentration chosen. Chromatograms of the resulting solutions 
gave excellent separation and resolution (Figure 6.2) and co-elution of excipients 
was not observed (Figure 6.3) at the same retention time as MP, EP and PP. 
The retention times are reported in Table 6.2. 
 
Table 6.2 - Retention times (min) of methyl p-hydroxy benzoate, ethyl p-hydroxy 
benzoate and propyl p-hydroxy benzoate 
Peak No.  Compound  Approximately RT (min) 
1 Methyl  p-hydroxy benzoate  2.90 
2 Ethyl  p-hydroxy benzoate  4.20 
3 Propyl  p-hydroxy benzoate  6.81  
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Figure 6.2 – Separation of combined p-hydroxy benzoic acid. Conditions: isocratic elution with 
aqueous solution of 52.5% (v/v) methanol containing 0.2 M potassium dihydrogen phosphate 
(pH 7.05), flow rate 2 mL/min, UV detection 254 nm, injection volume 20 µL, Waters µ-
Bondapak C18 column (300 x 3.9 mm). 
 
 
 
 
Figure 6.3 - Chromatogram of placebo without adding p-hydroxy benzoic acid. For 
experimental conditions see Figure 6.2. 
 
  
   48    
6.2 Step-by-step method validation  
 
For best practice, a similar approach was adopted in validation of this assay 
method as previously described in Chapter 5. 
 
The linearity test was performed using seven different amounts of MP, EP and 
PP in the range of 20-140% around the theoretical values (MP 10 µg/mL, EP and 
PP 2 µg/mL). Solutions corresponding to each concentration level were injected 
and linear regression analysis of the MP, EP and PP peak areas (y) versus MP, 
EP and PP concentration (×) were calculated (Table 6.3), MP (r
2 = 0.9999), EP 
(r
2 = 1.0000) and PP (r
2 = 0.9999).  
 
Intermediate precision was studied by assaying five samples prepared by 
different analysts, using a different HPLC column, on a different day. The RSD 
across the system and analysts were calculated and found to be less than 0.6% 
(Table 6.3) for each of the multiple sample preparations, which demonstrated 
excellent precision and reproducibility for this developed new assay method. 
 
The system precision was examined by analysing six determinations of the same 
batch of product at 100% of the test concentration. The samples were stored at 
25°C for six months. The RSD of the areas of each paraben peak were found to 
be less than 0.9% (Table 6.3), which confirmed that the method was very 
reproducible and sufficiently precise. 
 
Stability of sample and standard solutions were conducted and chromatographed 
immediately after preparation and then re-assayed after storage at room 
temperature for 24 hours.  The results given in Table 6.3 showed that there was 
no significant change (< 0.14% response factor) in combined p-hydroxy benzoic 
acid concentration over this period.  
 
A system suitability test was performed to determine the accuracy and precision 
of the system by injecting six replicate injections of combined p-hydroxy benzoic 
acid standard solutions. The RSD of the peak areas responses was measured. 
The RSD values were for MP (0.09%), EP (0.19%) and PP (0.24%) as can be 
seen in Table 6.3.  
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Table 6.3 - Method validation results of p-hydroxy benzoic acid 
Validation step  Parameter   MP  EP  PP  Acceptance 
criteria 
System precision  RSD (%)
a  0.037 0.582 0.827  x  <  2 
Method precision: 
Analyst 1 
RSD (%)
b  0.163 0.421 0.356  x  <  2 
Analyst 2  RSD (%)  0.365  0.529  0.561  x < 2 
Analyst 1 & 2  RSD (%)  0.300  0.480  0.444  x < 2 
Linearity (n = 7)
c  Correlation coefficient  0.9999  1.0000  0.9999  x > 0.9990 
Standard stability
d  % Change in response 
factors 
0.140 0.140 0.140  x  <  2 
Sample stability  % Change in response 
factors 
0.275 0.276 0.275  x  <  2 
System suitability  RSD (%) n = 6  0.09  0.19  0.24  x < 2 
a Six injections 
b Five preparations each, two injections of each preparation. 
c At 20, 40, 60, 80, 100, 120, 140% levels. 
d Two-day stability data. 
 
 
A known quantity of pure combined p-hydroxy benzoic acid was added to the 
sample to give a concentration range of 75-125% (n = 3) of that in a test 
preparation. These solutions were chromatographed and the amount of 
combined  p-hydroxy benzoic acid recovered calculated. Good recovery of 
combined p-hydroxy benzoic acid was observed as shown in Table 6.4. 
 
Injections of the extracted placebo were performed to demonstrate the absence 
of interference (specificity) with the elution of the combined p-hydroxy benzoic 
acid. These results demonstrated (Figure 6.3) that there was no interference 
from the other materials (excipients) in the liquid pharmaceutical formulation, and 
therefore confirmed the specificity of the analytical method.  
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Table 6.4 - Accuracy /recovery of combined p-hydroxy benzoic acid from samples with 
known concentration 
Amount of standard (mg)   
Sample 
Percent of 
nominal  Spiked Found 
Recovery 
(%, n = 3) 
RSD 
(%, n = 3) 
1 75  4.5 3.7  82.0  0.4 
2 100  9.0  8.4  94.0  0.7 
3 125  135 122  91.0  0.6 
 
 
6.3 Conclusion 
 
A new HPLC assay method with UV spectrophotometric detection was 
developed successfully for the determination of combined p-hydroxy benzoic 
acid preservatives. Preliminary studies during the method research and 
development phase illustrated the benefit of the step-by-step approach. The 
method was critically validated and the results obtained were accurate and 
precise with RSD ≤ 0.83% in each study and no significant interfering peaks 
were detected. The calibration curve were linear with correlation coefficient of 
>0.9999 for each preservative studied. The validated method was then submitted 
to the regulatory agency for product licence, which was successfully obtained. 
The method was then used for the routine quality control analysis (batch analysis 
and stability tests) of compounds in pharmaceutical products containing 0.3% of 
MP, EP and PP preservatives and the degradation products of the active 
compound. This method was successfully applied for the identification, 
quantitative analysis and stability tests of all compounds in the liquid 
pharmaceutical formulation for final product release. 
 
This research has made a significant and coherent contribution to new 
knowledge about the product including a more detailed approach to method 
validation has resulted in an acceptable validated method by the regulatory 
agency. Also new information on shelf life extension of the product containing p-
hydroxy benzoic acid preservatives has been obtained. 
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7  Method Development and Validation for the 
GC–FID Assay of p-Cymene in Tea Tree Oil 
Formulation 
 
 
Finally in this research programme, the validation approach was evaluated as 
applied to another analytical technique. Here, GC was successfully used to 
develop a novel assay for p -cymene content in tea tree oil formulation [9, 
appendix I]. This presented a different analytical problem because of the very 
complex nature of this natural product, GC was the technique of choice for this 
method. 
 
The use of essential oils in complementary medicine, particularly aromatherapy 
and also in the cosmetic and perfumery industry is becoming increasingly 
popular. The essential oil, which is distilled from the leaves of a tree Melaleuca 
alternifolia, commonly called tea tree is well known for its antimicrobial activity 
and has enjoyed increased medicinal uses in recent years. Oil of Melaleuca 
alternifolia (terpinen-4-ol type) is now clearly defined by the Draft ISO 4730. It 
sets a p-cymene content of not less than 0.5% and not more than 12%. 
Chemically p-cymene (I) is a 1-methyl-4-(1-methylethyl) benzene (Merck Index, 
1996) occurs in a number of essential oils.  
 
p-Cymene (I)  
 
p-Cymene concentration can rise to levels approaching its upper limit (see 
research paper 9, appendix I). Two pathways are operating here (Figure 7.1), 
one involving hydrolysis of the pi bond at C-4 to produce terpinen-4-ol, the other 
involving oxidation of the p-menthane skeleton to its benzene analogue, p-
cymene. The first pathway must involve water, naturally present in the oil through 
the steam distillation extraction process and possibly, trace volatile organic acids 
that may catalyse the reaction. The second pathway is well known in terpene  
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chemistry. However, the various oxidation agent and catalysts that are involved 
in tea tree oil degradation required further investigation.  
 
 
OH
α-Terpinene γ-Terpinene α-Terpinolene
Hydrolysis Oxidation
Terpinen-4-ol p-Cymene  
 
Figure 7.1 – End products of hydrolysis and oxidation of constituents of tea tree oil. 
 
 
7.1 Step-by-step new method development  
 
A similar systematic strategy was used in developing a new method for p-
cymene as discussed in Chapter 5. 
 
The method development for the assay of p-cymene was based on its chemical 
properties.  p-Cymene (CH3C6H4CH(CH3)2) is a non-polar molecule and, 
therefore, a non-polar solvent hexane (C6H14) was used as the diluent. The 
medium polarity five percent Carbowax was used for separation. The GC-FID 
parameters used in the method development were based on the boiling point 
(177.10  °C) and the flash point (47 °C) of p-cymene. The injection port and 
detector temperature were set to 220 °C and oven temperature was set to 100  
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°C. The oven programme was isothermal with a run time of 10 min. The head 
pressure was set to ensure a hydrogen flow of 36 mL/min. The split was then 
adjusted to 6:01. The solvent, column and acquisition parameters were chosen 
to be a starting point for the method development. However, the separations 
produced using these parameters were excellent. The retention time of p-
cymene was approximately 8.45 min with good peak shape and USP tailing was 
approximately 1.0. Additionally, preliminary precision and linearity studies 
performed during the development of the method showed that the 1.5 µL 
injection volume was reproducible and the peak response was significant at the 
analytical concentration chosen. Diluting the standard and sample in hexane 
gave solutions that could be injected directly (without further dilution, filtration or 
centrifugation). Chromatograms of the resulting solutions gave very good peak 
shapes (Figure 7.2 and 7.3) and co-elution of excipients was not observed on the 
same retention time as p-cymene. 
 
 
 
Figure 7.2 – Separation of p-cymene reference standard. Conditions: Phenomenex column 
packed 5% carbowax 20 m (6 x 0.25 mm) 80-100 mesh, hydrogen gas, FID, injector and 
detector temperature 220 °C, oven temperature 100 °C, flow rate 36 mL/min, injection volume 
1.5 µL. 
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Figure 7.3 – Separation of 100% tea tree oil sample. p-Cymene eluted at 8.46 min. 
Conditions: Phenomenex column packed 5% carbowax 20 m (6 x 0.25 mm) 80-100 mesh, 
hydrogen gas, FID, injector and detector temperature 220 °C, oven temperature 100 °C, flow 
rate 36 mL/min, injection volume 1.5 µL. 
 
 
7.2 Step-by-step method validation  
 
For best practice, a similar step-by-step approach was adopted in validation of 
this assay method as used in Chapter 5. 
 
Validation is a critical part of the development of a GC method. Although there is 
general agreement about what type of validation studies that should be done, 
there is great diversity in opinion as to how they are to be accomplished. The 
literature contains a variety of approaches to performing validation studies using 
gas chromatography (Robert & Eugene, 2004). This paper presents approaches  
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that serve as a basis to perform validation studies for most GC methods in 
compliance with the pharmaceutical and biotechnology fields. The validation 
characteristics performed were linearity, range, specificity, accuracy, precision 
(repeatability and intermediate precision), limit of detection and limit of 
quantitation. 
 
The linearity was studied in the concentration range 20-120 µg/mL.  Six solutions 
were prepared corresponding to 20, 40, 60, 80, 100, and 120% of the nominal 
analytical concentration (100 µg/mL) and the following regression equation was 
found by plotting the peak area (y) versus the p-cymene concentration (x) 
expressed in µg/mL: y = 354.05x + 0.218 (r
2 = 0.9995). The analyte response is 
linear across 80-120% of the target p-cymene concentration. 
 
The precision was examined by analysing six different samples by only one 
operator. The repeatability (within-run precision) was evaluated by only one 
analyst within one day, whereas reproducibility (between-run precision) was 
evaluated for three different days. The RSD values for within-run precision was 
0.13% and for between-run precision was 0.66% (Table 7.1), therefore meeting 
the acceptance criteria for the chromatographic p-cymene assay. 
 
 
Table 7.1 - Within and between-run precision results for p-cymene in 100% tea tree oil 
formulation 
Within-run precision  Mean between-run precision  (n = 3 days)   
Injection No.  Area (µV)  Retention 
time (min) 
Area (µV)  Retention time 
(min) 
1 29.2152  8.46  21.1505 8.45 
2 29.0633  8.45  21.2953 8.45 
3 29.6717  8.45  21.3440 8.45 
4 28.3922  8.46  21.3291 8.46 
5 28.5053  8.45  21.3453 8.45 
6 28.2665  8.45  20.9958 8.45 
Mean (6)  28.8523  8.45  21.2450  8.45 
RSD (%)  0.13 0.06  0.66  0.05 
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The accuracy of the method was determined by fortifying sample with known 
amounts of the p-cymene reference substance at four concentration levels (0.5, 
0.10, 0.05 and 0.01 mg/mL) and injected in triplicate. Mean recoveries for the 
samples analysed were found to be 95.3%. 
 
The lower limit of detection for p-cymene was found to be (signal-to-noise = 3) 
2.08 µg/mL. The LOQ values for p-cymene were found to be (signal to noise = 
10) 10.39 µg/mL and RSD less than 2% for three replicate injections. 
 
Assay interference (specificity) was investigated by injecting 12 month old 
stability solutions of tea tree oil. No interfering peaks were observed. Therefore, 
this method was specific for p-cymene. 
 
7.3 Stability  study 
 
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety 
of environmental factors such as temperature, humidity and light, and enables 
storage conditions to be recommended and re-test and shelf lives to be 
established.  
Tea tree oil is susceptible to oxidation and this is highlighted by the analytical 
data (Table 7.2) presented for two batches of tea tree oil. Samples of tea tree oil 
containing p-cymene content were packed in sealed dark brown glass bottles (10 
mL) and stored at room temperature. The samples were withdrawn periodically 
(0, 1, 2, 3, 6, 9, 12 and 24 months) and the validated method was utilized 
successfully for analysing these stability samples. The data obtained from 
stability batches is evident that the assay is suitable for the quantitative analysis 
and stability testing of p-cymene content in the tea tree oil formulation. 
 
Table 7.2 - Stability data for p-cymene content in tea tree oil over 24 months 
Batch #  Specification  Interval time in months 
    0 1 2 3 6  9  12  24 
1  0.5-12%  2.2 2.8 2.7 2.4 3.1  3.0  3.5  10.1 
2  0.5-12%  2.3 2.5 2.4 2.9 3.3  3.6  3.8  10.3 
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In this stability investigation, it could be seen that p-cymene concentration can 
rise to levels approaching its upper limit (maximum 12%). The key chemical 
indicator of oil treatment during processing and storage is p-cymene and 
elevated levels are usually an indication of poor storage conditions, old oil or 
harsh treatment during extraction.  
 
Tea tree oil undergoes oxidation on storage via a number of different routes, 
some of which actually enhance oil, quality during the early stages. For long term 
storage for large quantities of neat oil stainless steel and aluminium, along with a 
nitrogen purge, provide the greatest stability (approximately two years). Dark 
glass with caps containing an impenetrable liner provides excellent long-term 
storage of small quantities. Stability of formulated products in glass is far 
superior to that in high-density polyethylene (HDPE) and polypropylene. 
However, laminates that incorporate aluminium or a fluorinated liner will enhance 
shelf life, although this may be dependent on the formulation matrix and tea tree 
oil concentration. 
 
7.4 Conclusion 
 
A new analytical method for the assay of p-cymene from a tea tree oil 
formulation was developed and validated using validated gas chromatography 
system. The validation study showed good linearity, (r
2 = 0.9995) sensitivity, 
accuracy and precession (RSD ≤ 0.66%). The proposed procedure was used in 
a quality control laboratory for analysis of formulations containing p-cymene 
products for final release. 
 
This research has made a significant and coherent contribution to new 
knowledge including new validated GC method; new information on active p-
cymene content; new information on tree tea oil product; a more detailed 
approach to method validation; a robust validated method and newly identified 
knowledge about product and shelf life extension. 
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8  Overall Conclusion and Suggestions for 
Further Work  
 
 
Efficient analytical method validation is a critical element in the development of 
pharmaceuticals. Indeed, the principle of the validation of these methods is today 
widely spread in all the domains of activities where measurements are made. 
Nevertheless, the simple question of acceptability or not of an analytical method 
for a given application, remains incompletely determined in several cases 
despite the various regulations relating to the good practices (GLP, GMP) and 
other documents of normative character (ICH, USP, FDA). There are many 
official documents describing the criteria of validation to be tested, but they do 
not propose any simple step-by-step approaches to method development and 
validation activities and limit themselves most often to the general concepts. 
 
For those reasons, critical analysis of the situation in the author’s papers with 
respect to simple and step-by-step approach to analytical method development 
and validation has proved to be a very major contribution to new knowledge. A 
number of scientists and experts on method development and validation have 
used as guidelines and cited these papers as authoritative work.  These papers 
have been cited in the field of advanced analytical chemistry books, high impact 
critical peer-reviewed journals and in regulatory compliance training courses / 
workshops around the world. 
 
Application of identified good practice has led to a number of very sound, 
reliable, rapid and robust methods, each of which has performed well in practice 
and especially in some cases, made a major contribution to new knowledge and 
the development of the substance/product involved. 
 
The concept of validation covered in the literature is mostly associated with 
development and validation of chromatographic methods. The description of 
equipment qualification is also discussed in the literature to a lesser extent 
(Grisanti & Zachowski, 2002; Zanetti & Huber, 1996; Hall & Dolan, 2002). 
However, the description of instrument qualification generally does not include  
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the need to validate the computer aspect of the instrument (software and 
computer hardware), which should be considered an important part of the 
qualification package prior to method validation. 
 
Another one of the critical issues that have not been addressed by the 
consensus reports is when method validation is necessary. In the current highly 
cost-conscious environment, the balance of costs and benefits is an issue. The 
literature and regulatory agencies contain diverse approaches to performing 
method validation, as discussed above; there is a need for a single guideline 
worldwide on performing method validation. ICH should expand their effort on 
method validation globally for more input and set the minimum standard “one 
world – one standard” which ensures patient safety. Alternative guidelines to ICH 
are not preferred; the world should stay with ICH to achieve global 
harmonisation. This is because it is easier to revise and build upon existing 
guidelines that are already in operation. The guideline should cover step-by-step 
approaches from drug development to marketing authorisation. The guideline 
should also cover all the pre-validation requirement activities such as analytical 
instrument qualification (validation), which is another aspect of method 
validation. The benefits to the regulated industry of achieving the desired state 
(globally harmonised) will ensure, better quality, less recalls, less supplements, 
and facilitate new technology and continuous improvement. Focus will be on 
critical quality attributes and controls and will reduce regulatory burden of post 
approval changes.  
 
USP and FDA have accepted ICH documents and have updated general 
chapters but old methods do not meet the criteria (e.g., TLC) and are currently 
not being updated. A major challenge to many pharmaceutical industries of today 
who still use old validated methods is that they need to upgrade/revalidate in 
order to meet current regulatory standards. The USP28-NF23 contains over 
4000 monographs and over 180 general chapters. Approximately 200 drug 
substance, excipient, and drug product monographs are needed. Approximately 
800-1200 current monographs need to be updated.  
 
In considering the balance, the question of where things are going must be 
asked. Should a start be made with a blank piece of paper and a “desired state”  
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for pharmacopoeias and the public standards be developed. Does it make sense 
to retrofit for compendial standards from 1820 to the “21
st century? The testing of 
compendial standards and the specification process has remained nearly 
unchanged. Adoption for the future is a must and re-assessment, re-evaluation 
and evolution is necessary. It is critical for the USP to be engaged with the 
changes and paradigm shift occurring at the FDA. Specifications must be based 
on FDA approved materials. The purpose of a monograph needs to be re-
assessed. The role of monograph in release, stability and marketing surveillance 
needs to be re-evaluated. 
 
The evolution and application of general chapters also needs to be considered: 
How will they be impacted by the changes and be applied (enforced) in the 
future? How will general chapters be developed to adapt to the new paradigm 
and how will existing chapters be modified? Will there be dual standards in the 
USP to accommodate the new approaches and how will content uniformity be 
addressed? Should it be addressed in the USP or should the current chapter 
remain and companies left with the option of different specifications / analytical 
methods based on agreements with the FDA? Chapters should not duplicate 
efforts underway in other areas (e.g. American Society for Testing and 
Materials (ASTM International Standards). 
 
In Global Harmonisation: the path that the USP takes must be carefully 
considered. Since the USP has been engaged with the Pharmacopoeial 
Discussion Group (PDG) on harmonisation of general chapters and monographs 
it is important to move forward in collaboration with the other Pharmacopoeias 
and not in isolation. Work that has been done by the PDG must not be undone. 
The USP should work with the PDG to ensure that the current harmonised items 
are not negatively impacted and also work prospectively to harmonise new 
concepts. 
 
Also input from the pharmaceutical industry and other users of their volumes is, 
therefore, essential in the provision of information as to what is most needed in 
the prioritisation and harmonisation of the work programmes. In a continually 
changing environment the PDG looks to industry to produce suggestions as to 
what issues need to be addressed in the formulation of its work programmes.  
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Industry professionals are, therefore, urged to take a keen and active interest in 
the work of the PDG, to monitor its progress by reading the appropriate forums 
and to let it know where major problems are occurring.  
 
In overall conclusion, the status quo is no longer adequate and evolution is 
necessary. In order to prepare for the future the role of monographs and general 
chapters must be critically evaluated and what changes that must occur must be 
considered. These must be linked to the changes occurring at FDA and industry. 
The USP must engage the FDA, industry and PDG in the evolution process. 
In final summary, the authors work as set out in the submitted papers provides a 
significant contribution to the knowledge base upon which then future 
development must take place and has included: 
 
i)  A critical review of the literature on analytical method development and 
validation – [1-4, appendix I]; 
ii)  Application of sound experimental modern analytical chemistry 
techniques and development of rapid, simple, reliable and very robust 
new assay methods – [5-9, appendix I]; 
iii)  Independent research that makes a significant and coherent contribution 
to new knowledge  – [5-9, appendix I]; 
iv)  The creation and interpretation of knowledge, which extends the forefront 
of discipline through original peer-reviewed and validated research – [5-
9, appendix I]; 
v)  Development of strategies to implement new processes at work place – 
[1-9, appendix I]. 
 
The author’s contribution to the development of pharmaceutical standards for 
use in decision making and to achieve compliance with ICH, FDA and USP have 
been demonstrated, and the author’s input to this development has been 
described. The author’s development strategy for implementing analytical 
method development and validation systematic approaches with high degree of 
research standards has been demonstrated. The role of future of USP, FDA and 
ICH in global harmonisation in the field of analytical method validation has been 
discussed. The large number of citations already made to the submitted papers  
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verifies the fact that these combined constitute a major and coherent contribution 
to new knowledge. 
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